$PLRZ News

Polyrizon Announces Successful Completion Enrollment of all 120 Patients in U.S. Clinical Study of NASARIX Allergy Blocker

Polyrizon Completes Participant Enrollment In Its Trial Of NASARIX To Treat Airborne Allergens

Polyrizon Files for U.S. Patent Application to Expand IP Moat Around Intranasal Drug-Delivery Platform

Polyrizon Files New US Divisional Patent Application With USPTO, Further Expanding Its IP Portfolio Relating To Proprietary Mucoadhesive Technology

Polyrizon Enrolls First Patient in U.S. Clinical Study of NASARIX (PL-14) Allergy Blocker

Polyrizon Enrolls First Patient In U.S. NASARIX Allergy Blocker Trial, Entering Clinical Stage

Polyrizon Ltd. Announces Closing of $4.0 Million Registered Direct Offering and Private Placement

Polyrizon Ltd. Announces $4.0 Million Registered Direct Offering and Private Placement

Polyrizon Completes All Five U.S. Site Contracts for NASARIX™ First-in-Human Allergy Study

Polyrizon Completes Clinical Site Network for NASARIX™ Study and Advances Toward Patient Enrollment

Polyrizon Completes Contracting With Fourth, Fifth Clinical Facilities Participating In Its Clinical Trial Of NASARIX Allergy Blocker

Polyrizon Reports NASARIX Biocompatibility Results, Supporting Advancement To First-In-Human Clinical Trial

Polyrizon shares climb after NASARIX passes key biocompatibility testing (PLRZ)

Polyrizon Announces Successful Results for NASARIX™ Biocompatibility Program, Supporting Advancement Towards First in Human Clinical Trial

Polyrizon Makes Strong Progress: Receives Central IRB Approval for its Allergy Blocker Clinical Trial

Polyrizon Receives Central IRB Approval To Begin First Human Clinical Trial For NASARIX, Nasal Spray Designed To Block Airborne Allergens

Polyrizon Receives Notice of U.S. Patent Publication for Mucoadhesive Drug Delivery Platform

Polyrizon Advances NASARIX™ Development with Key Human Study to Characterize Nasal Residence Time and Support FDA Regulatory Pathway

Polyrizon Launches Human Study With Top European Medical Center To Validate NASARIX Allergy Blocker's Nasal Residence Time

Polyrizon Receives Notice of European Patent Publication for Innovative Mucoadhesive Nasal Drug Delivery Technology